262 related articles for article (PubMed ID: 28733707)
1. Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Neurotox Res; 2017 Nov; 32(4):639-648. PubMed ID: 28733707
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro.
Zakrocka I; Turski WA; Kocki T
Eur J Pharmacol; 2016 Oct; 789():308-312. PubMed ID: 27423316
[TBL] [Abstract][Full Text] [Related]
4. Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.
Chmiel-Perzyńska I; Perzyński A; Olajossy B; Gil-Kulik P; Kocki J; Urbańska EM
J Diabetes Res; 2019; 2019():4957879. PubMed ID: 31737685
[TBL] [Abstract][Full Text] [Related]
5. Cerebrolysin lowers kynurenic acid formation--an in vitro study.
Baran H; Kepplinger B
Eur Neuropsychopharmacol; 2009 Mar; 19(3):161-8. PubMed ID: 19008081
[TBL] [Abstract][Full Text] [Related]
6. Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro.
Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
Neurotox Res; 2019 Jan; 35(1):244-254. PubMed ID: 30178287
[TBL] [Abstract][Full Text] [Related]
7. The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro.
Zakrocka I; Kocki T; Turski WA
Pharmacol Rep; 2017 Jun; 69(3):536-541. PubMed ID: 28364692
[TBL] [Abstract][Full Text] [Related]
8. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
Koshy Cherian A; Gritton H; Johnson DE; Young D; Kozak R; Sarter M
Neuropharmacology; 2014 Jul; 82():41-8. PubMed ID: 24647121
[TBL] [Abstract][Full Text] [Related]
9. Dual effect of DL-homocysteine and S-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid.
Luchowska E; Luchowski P; Paczek R; Ziembowicz A; Kocki T; Turski WA; Wielosz M; Lazarewicz J; Urbanska EM
J Neurosci Res; 2005 Feb; 79(3):375-82. PubMed ID: 15605380
[TBL] [Abstract][Full Text] [Related]
10. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry.
Guidetti P; Hoffman GE; Melendez-Ferro M; Albuquerque EX; Schwarcz R
Glia; 2007 Jan; 55(1):78-92. PubMed ID: 17024659
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.
Bortz DM; Wu HQ; Schwarcz R; Bruno JP
Neuropharmacology; 2017 Jul; 121():69-78. PubMed ID: 28419874
[TBL] [Abstract][Full Text] [Related]
12. Kynurenic acid metabolism in the brain of HIV-1 infected patients.
Baran H; Hainfellner JA; Kepplinger B; Mazal PR; Schmid H; Budka H
J Neural Transm (Vienna); 2000; 107(10):1127-38. PubMed ID: 11129102
[TBL] [Abstract][Full Text] [Related]
13. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome.
Baran H; Cairns N; Lubec B; Lubec G
Life Sci; 1996; 58(21):1891-9. PubMed ID: 8637415
[TBL] [Abstract][Full Text] [Related]
14. D-Cycloserine lowers kynurenic acid formation--new mechanism of action.
Baran H; Kepplinger B
Eur Neuropsychopharmacol; 2014 Apr; 24(4):639-44. PubMed ID: 24189377
[TBL] [Abstract][Full Text] [Related]
15. Kynurenic Acid Levels and Kynurenine Aminotransferase I, II and III Activities in Ganglia, Heart and Liver of Snail Helix Pomatia.
Kronsteiner C; Baran H; Kepplinger B
Cell Physiol Biochem; 2023 Aug; 57(4):279-297. PubMed ID: 37597169
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition.
Chang C; Fonseca KR; Li C; Horner W; Zawadzke LE; Salafia MA; Welch KA; Strick CA; Campbell BM; Gernhardt SS; Rong H; Sawant-Basak A; Liras J; Dounay A; Tuttle JB; Verhoest P; Maurer TS
Mol Pharmacol; 2018 Aug; 94(2):823-833. PubMed ID: 29853495
[TBL] [Abstract][Full Text] [Related]
17. Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations.
Herédi J; Cseh EK; Berkó AM; Veres G; Zádori D; Toldi J; Kis Z; Vécsei L; Ono E; Gellért L
Brain Res Bull; 2019 Mar; 146():185-191. PubMed ID: 30639278
[TBL] [Abstract][Full Text] [Related]
18. L-cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II.
Kocki T; Luchowski P; Luchowska E; Wielosz M; Turski WA; Urbanska EM
Neurosci Lett; 2003 Jul; 346(1-2):97-100. PubMed ID: 12850557
[TBL] [Abstract][Full Text] [Related]
19. Kynurenic acid and kynurenine aminotransferase in heart.
Baran H; Amann G; Lubec B; Lubec G
Pediatr Res; 1997 Mar; 41(3):404-10. PubMed ID: 9078543
[TBL] [Abstract][Full Text] [Related]
20. 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats.
Luchowski P; Luchowska E; Turski WA; Urbanska EM
Neurosci Lett; 2002 Sep; 330(1):49-52. PubMed ID: 12213632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
